The covid-19 pandemic has accelerated the development of innovative vaccines and demonstrated the enormous potential of vaccine platform technologies. Rapid development, good effectiveness and scalability to meet a global demand have contributed to the successful development of the mRNA covid-19 vaccines.
The use and expansion of these novel platforms and the further improvement of vaccine development, such as broad-spectrum vaccines that can induce a global, serotype-independent protection, will better prepare us in the event of a new outbreak. But also new vaccine delivery systems and vaccines that are more affordable, easy to store, transport, and administer will help to prevent us from existing and future emerging pathogens.
Therapeutic vaccines are also experiencing spearheading innovations with new scientific modalities and technical techniques, driving the next generation of immunotherapies for oncology, immune disorders and rare diseases. The types of immunotherapy treatments available are proliferating, with approved immune checkpoint inhibitors (ICIs) and cellular therapies like chimeric antigen receptor (CAR) T cells and tumor-infiltrating lymphocyte (TIL) therapy, as well as other modalities, such as oncolytic virus therapy.
During this networking afternoon, high quality presentations, including an informative talk of VLAIO/SPW/Innoviris explaining the interregional R&D collaboration programme BELCOO, and pitches from our member network will be followed by a B2B partnering session.
This means that presenters can directly harvest the fruits of their talk or pre-schedule meetings with potential partners via the networking tool – powered by B2Match!
Meet our speakers:
Agenda
13:00 Registration and welcome drink
13:30 Welcome word by BioWin & Flanders Vaccine
13:40 Speakers session
- The use of Artificial Intelligence for vaccine development – Pieter Meysman, ImmuneWatch
- New class of cancer vaccine based on an off-the-shelf Antigen Presenting Cell line (PDC*line) – Eric Halioua, PDC*line Pharma
- BEL-COO programme: Financial support for interregional collaboration – Patrica Menten, VLAIO / Stijn Maas, Innoviris /Pierre Demoitie, SPW
14:55 Pitch session
- Robust Preclinical Vaccine Development package: the key towards a successful IND! – Olivier Vanloocke, CER Groupe
- Nanotechnologies enabling the delivery of nucleic acid vaccines and therapeutics – Rein Verbeke, Ghent University
- The yogurt vaccine: a unique solution for broader vaccination coverage – Perjan Pleunis, LivingMed BioTech
- In vitro functional validation of candidate TCRs and CARs for adoptive cell therapy – Diana Campillo-Davó, UAntwerp
- Using artificial intelligence to identify infectious disease drug targets & treatments: improving the drug discovery process – Bruno Speder, Poolbeg Pharma
- Novel viral vector to develop multivalent vaccines – Benjamin Damien, Sagitta Biotech
- QuantitativeTCR Seq, an innovative immuno-monitoring platform for the research and development of cancer vaccines and related biomarkers – Jean-Luc Henrioul, Seqalis
- Opportunity for CCR8 Biologics in Oncology and Beyond – Susanne Ständer, VIB-VUB
15:40 Coffee Break & Start Partnering
17:00 End Partnering
Target group
The event is open to academia, industry and governmental organisations active in the field of vaccines and immunotherapy.
Interested in pitching?
The call for abstracts is closed.
Do you have expertise within the field of vaccine development, immunotherapy in human or animal health that contributes to the development of next generation vaccines and immunotherapy? Then here’s your opportunity to take the floor and present your expertise to an audience of potential partners.
A committee of the BioWin – Flanders Vaccine team will review all applications and inform you about the selection of the pitches in the first week of May.
What’s in it for you?
- You’ll have the opportunity to present your project to an audience of interested partners
- You gain additional visibility for the B2B session of the event
- You can take advantage of the BELCOO programme that stimulates cross-border collaborations
How can I participate?
Interested to get to know the important Belgian players active in the development of vaccines and immunotherapy, join us and register before May 9th 2023.
- Flanders Vaccine/BioWin member: 70 EUR (VAT excl.)
- Non-member: 120 EUR (VAT excl.)
Practical information
- Venue: Park Inn by Radisson Leuven, Martelarenlaan 36, 3010 Leuven
- Access: How to get there?
- Date: 16 May 2023
- Timing: 1:30 -5:00 PM
